echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Regenerative meta-start antibody cocktail therapy Phase 3 clinically used to prevent new crown virus infection.

    Regenerative meta-start antibody cocktail therapy Phase 3 clinically used to prevent new crown virus infection.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    REGN-COV2 consists of two monoclonal antibodies combined with the key receptor binding domain (RBD) of the new coronavirus sting proteinThe RBD binding sites of the two antibodies are different, so the combination can reduce the virus's ability to escape monoantibody therapy by producing genetic mutationsPreclinical research on the two antibodies has been published in the journal ScienceIn Phase 1 clinical trials, an independent data monitoring committee's review of the initial queue of 30 inpatient and non-inpatient COVID-19 patients found that REGN-COV2 showed good safetyThe phase 3 prevention trial, which is being conducted at about 100 research centers and is expected to recruit 2,000 patients in the United States, will assess the status of SARS-CoV-2 infectionThe Phase 2/3 treatment pilot programme was conducted in approximately 150 research centres in the United States, Brazil, Mexico and Chile in patients in hospital (estimated number of participants, 1850) and non-inpatients (estimated number of participants, s.1050), and will evaluate virology and clinical endpoints, with preliminary data expected later this summerAll trials are adaptive and the final number of patients in the group will depend on the progress of the trial and the results of the Phase 2 studyDrGeorge DYancopoulos, Co-founder, President and Chief Scientific Officer of Regeneration, said, "We are simultaneously conducting adaptive trials to provide a potential solution to prevent and treat COVID-19 infection as quickly as possible." We are pleased to work with NIAID on REGN-COV2 to seek further ways to stop the spread of the virusReferences: Regeneron Announces Start of REGN-COV Phase2 3 COVID-19 Prevention Trial in The Collaboration with National Institute of Allergy and Post Diseases (NIAID)Retrieved 2020-07-06, from the original title: Prevention of new crown virus infection, regenerative meta-start antibody cocktail therapy Phase 3 clinical trial.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.